Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA 30-day sign-off on third-party device decisions planned for pilot program.

This article was originally published in The Gray Sheet

Executive Summary

THIRD-PARTY DEVICE REVIEW PILOT: FDA SIGN-OFF WITHIN 30 DAYS on 510(k) decisions made by third-party groups likely will be a performance goal for the pilot program. Adopting a suggestion from the Health Industry Manufacturers Association ("The Gray Sheet" June 26, p. 4), FDA is expected to set itself a 30-day deadline for reviewing and signing off on third-party "substantial equivalence" determinations.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel